CAPR logo

CAPRCapricor Therapeutics Inc

$28.57
$1.90
(7.29%)
Today
Closed $27.95
$0.62
(2.22%)
After Hours
Updated: 06:15 PM EDT
EarningsAug 11
Mkt Cap$1.51B
Vol1.46M
News
all
press releases
All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6%
An oral argument on a dispute between Nippon Shinyaku, its U.S. subsidiary, NS Pharma, and Capricor is scheduled for Wednesday.
Stocktwits
News Placeholder
More News
News Placeholder
Capricor Therapeutics Q1 2026 Earnings Call Transcript
read more...
Benzinga
News Placeholder
Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy
Capricor sued Nippon Shinyaku over Deramiocel distribution terms, citing pricing issues and patient access risks.read more...
Benzinga
News Placeholder
Nasdaq, S&P 500 Futures Rise Ahead Of Jobs Report As Iran Ceasefire Holds: Why NVDA, IREN, CRWV, RKLB, UPWK, CAPR Are In Focus
Data from Stocktwits shows that retail traders’ sentiment has remained ‘bullish’ on SPY and QQQ this week.
Stocktwits
News Placeholder
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review
Capricor is seeking court approval to pursue an alternative commercialization path for Deramiocel and wants parts of the agreement terminated.
Stocktwits
News Placeholder
Capricor Therapeutics (CAPR) Projected to Post Earnings on Tuesday
Capricor Therapeutics (NASDAQ:CAPR) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at...
MarketBeat
News Placeholder
Oppenheimer & Co. Inc. Cuts Stock Holdings in Capricor Therapeutics, Inc. $CAPR
Oppenheimer & Co. Inc. trimmed its position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 40.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 80,813 shares of the biotechnology company's stock after selling 54,600 s...
MarketBeat
News Placeholder
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 7.1% - Still a Buy?
Capricor Therapeutics (NASDAQ:CAPR) Trading 7.1% Higher - What's Next...
MarketBeat
News Placeholder
CAPR Stock In Focus: Ex-Exec Eyed For FDA Role Says Drug Approvals Are Not ‘Best-In-Class’ Signals
Former Capricor executive Houman David Hemmati said FDA approval should be viewed as a “building permit,” not proof a drug is the best option.
Stocktwits
News Placeholder
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5% - What's Next?
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5% - Should You Sell...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.